Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients.

INTRODUCTION

Leptin has lipid peroxidation properties in healthy individuals. Here we aimed to study the correlation between serum-oxidized low-density lipoprotein (ox-LDL) and leptin levels in patients with type 2 diabetes. We also studied the effect of metformin therapy on the correlation between serum ox-LDL and leptin levels in patients with newly diagnosed diabetes.

METHODS

We performed a cross-sectional study on two groups of patients with type 2 diabetes stratified according to (1) patients with newly diagnosed diabetes and (2) patients with long-standing diabetes plus healthy controls. Patients with newly diagnosed diabetes were followed for 3 months after the initiation of metformin therapy.

RESULTS

Patients with type 2 diabetes had a higher serum ox-LDL, ox-LDL/LDL ratio, waist circumference, fasting blood sugars (FBSs), hemoglobin A1C (HbA1C), triglyceride, homeostatic model assessment of insulin resistance (HOMA-IR) and a lower serum leptin levels than controls. Serum ox-LDL, ox-LDL/LDL ratio (0.08 (0.08-0.12) vs. 0.06 (0.05-0.08), P<0.001) and HOMA-IR (3.26±0.23 vs. 2.93±0.32; P<0.01) were decreased when serum leptin levels (15.9±1.6 vs. 21.4±2.5, P<0.01) were increased after 3 months of metformin therapy. This remained significant after multiple adjustments for age, body mass index, FBS, HbA1c, and HOMA-IR. Leptin was significantly correlated with ox-LDL/LDL ratio in controls (r=0.78, P<0.01), and in patients with newly diagnosed diabetes (r=0.4, P<0.05), after metformin therapy. There were not any correlation between leptin and ox-LDL/LDL ratio in patients with long-standing diabetes and patients with newly diagnosed diabetes before treatment.

DISCUSSION

Metformin restores the positive correlation between serum ox-LDL and leptin levels in patients with type 2 diabetes.